These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33087441)

  • 21. Impact of Stent Type and Presence of Vasospastic Angina on Long-Term Prognosis.
    Hata R; Oka N; Kubo S; Kuwayama A; Ohya M; Shimada T; Miura K; Amano H; Hyodo Y; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Goto T; Kadota K
    Circ J; 2018 Jan; 82(2):469-476. PubMed ID: 28659551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
    Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial.
    De Filippo O; Bianco M; Tebaldi M; Iannaccone M; Gaido L; Guiducci V; Santarelli A; Zaccaro L; Depaoli A; Vaudano P; Quadri G; Gagnor A; Boccuzzi G; Solitro F; Cortese G; Guarnaccia C; Tore D; Veltri A; Franchin L; Angelini F; Garbo R; Giammaria M; Varbella F; Marchisio F; Fonio P; De Ferrari GM; Cerrato E; Campo G; D'Ascenzo F
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33122421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
    Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
    Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry.
    Jensen JK; Jensen LO; Terkelsen CJ; Lassen JF; Tilsted HH; Hansen KN; Maeng M; Thuesen L; Thayssen P
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):260-5. PubMed ID: 22511512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
    Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).
    de Belder A; de la Torre Hernandez JM; Lopez-Palop R; O'Kane P; Hernandez Hernandez F; Strange J; Gimeno F; Cotton J; Diaz Fernandez JF; Carrillo Saez P; Thomas M; Pinar E; Curzen N; Baz JA; Cooter N; Lozano I; Skipper N; Robinson D; Hildick-Smith D;
    J Am Coll Cardiol; 2014 Apr; 63(14):1371-5. PubMed ID: 24216285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
    Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial.
    Kelbæk H; Høfsten DE; Køber L; Helqvist S; Kløvgaard L; Holmvang L; Jørgensen E; Pedersen F; Saunamäki K; De Backer O; Bang LE; Kofoed KF; Lønborg J; Ahtarovski K; Vejlstrup N; Bøtker HE; Terkelsen CJ; Christiansen EH; Ravkilde J; Tilsted HH; Villadsen AB; Aarøe J; Jensen SE; Raungaard B; Jensen LO; Clemmensen P; Grande P; Madsen JK; Torp-Pedersen C; Engstrøm T
    Lancet; 2016 May; 387(10034):2199-206. PubMed ID: 27053444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial.
    Généreux P; Bettinger N; Redfors B; Lee AC; Kim CY; Lee MS; Shlofmitz RA; Moses JW; Stone GW; Chambers JW
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):369-77. PubMed ID: 27084293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical outcomes after coronary artery bypass graft versus everolimus-eluting stent implantation in chronic hemodialysis patients.
    Kumada Y; Ishii H; Aoyama T; Kamoi D; Sakakibara T; Umemoto N; Ito R; Takahashi H; Murohara T
    Coron Artery Dis; 2018 Sep; 29(6):489-494. PubMed ID: 29668554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
    Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.